Latest Headlines

Latest Headlines

Judge turns down motion to appoint examiner or trustee in Biovest bankruptcy case

A Florida judge has ruled that it will not appoint an examiner or Chapter 11 trustee in BioVest International's bankruptcy case.

PolyMedix defaults and hands over a PhII antibiotic to bankruptcy court

Just two weeks after the Radnor, PA-based biotech floated a plan for a reverse split designed to get the penny stock player onto Nasdaq, the company's acting CEO and a pair of directors handed in their resignations and the developer filed for Chapter 7.

Baxter snags hemophilia candidate in $185M deal with Ipsen and broke biotech

Baxter International ($BAX) is grabbing a hemophilia A candidate in late-stage development from partners whose collaboration ran aground last year.

Troubled sequencing pioneer Helicos shelters in bankruptcy court

Delisted and largely dumped by investors after a pair of restructurings failed to cure what ailed it, Cambridge, MA-based Helicos BioSciences ($HLCS) has stepped into bankruptcy court seeking Chapter 11 protection for the genomic sequencing company.

Boston-area pharma plant goes up for auction to pay debts

A Boston-area plant that French drugmaker Ipsen had poured tens of millions of dollars into will be included in an auction of assets now that its partner, Inspiration Biopharmaceuticals, has filed for Chapter 11 bankruptcy protection.

Ipsen braces for $153M write-off as troubled biotech partner declares bankruptcy

Four months ago Inspiration Biopharmaceuticals was preparing for its commercial launch of a late-stage hemophilia therapy. Then in July the FDA clamped a clinical hold on the lead program and today the Cambridge, MA-based biotech's partner and primary financial backer Ipsen ($IPN) revealed that Inspiration had filed for Chapter 11 bankruptcy protection as it prepared for a sale of its assets through the courts.

Struggling Tengion threatens bankruptcy as it scrambles for cash

After burning through a disappointing $30 million IPO haul from 2010, the regenerative medicine biotech Tengion is signaling that it's scraping the bottom of the bank account and may have to file for bankruptcy protection if it can't raise fresh funds soon.

Manufacturing, pricing problems lead to K-V bankruptcy

Problems that began three years ago with K-V Pharmaceuticals hiding manufacturing lapses from the FDA have escalated into a Chapter 11 bankruptcy filing by the maker of Makena, a drug to prevent premature birth.

K-V Pharma travels bankruptcy route after suing FDA

Accusing regulators of failing to protect its birth drug, K-V Pharmaceutical has filed for bankruptcy with debts listed at $728.3 million and assets valued at $236.6 million, Reuters reported over the weekend.

RIP: After long illness, Genta finally opts to liquidate

After struggling for four years under the weight of a failed late-stage study for a lead cancer drug, long-time penny stock company Genta ($GNTA) is giving up the ghost. The biotech filed an 8-K today outlining its last remaining option: Chapter 7 bankruptcy liquidation.